معرفی
D. Andrew Wellman is an Associate Professor of Medicine at Harvard Medical School and a Medical Doctor in the Division of Sleep and Circadian Disorders at Brigham and Women's Hospital. He serves as Director of the Sleep Disordered Breathing Lab and Sleep Medicine Consultation Service, focusing on translational research and clinical management of sleep-disordered breathing.
His research centers on pathophysiological mechanisms of obstructive sleep apnea (OSA), including upper airway collapse dynamics, arousal threshold, hypoxic burden, and loop gain. Key interests encompass endotype-based treatment personalization, novel therapies like hypoglossal nerve stimulation and pharmacological combinations (e.g., atomoxetine/pimavanserin), and cardiovascular consequences of sleep apnea. His work bridges physiological laboratory findings with scalable clinical applications.
Analysis of recent publications reveals concentrated efforts on translating OSA endotyping into clinical practice, with emphasis on predicting treatment response for nerve stimulation and CPAP. His research identifies high-risk physiological markers (hypoxic burden, heart rate acceleration) for cardiovascular outcomes and addresses racial disparities in OSA diagnosis through desaturation criteria validation.
Dr. Wellman leads the Sleep Disordered Breathing Lab at Brigham and Women's Hospital, which integrates drug-induced sleep endoscopy, polysomnography, and computational modeling to characterize upper airway dynamics. The lab conducts NIH-funded clinical trials evaluating combination therapies and develops physiological metrics for precision medicine approaches in sleep apnea management.
